The self-injections market size has grown strongly in recent years. It will grow from $10.22 billion in 2025 to $11.04 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to growth in chronic disease prevalence, increasing availability of injectable biologics, rising preference for home-based treatment, expansion of specialty pharmaceuticals, improvements in injection device ergonomics.
The self-injections market size is expected to see strong growth in the next few years. It will grow to $15.05 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for self-care therapies, rising adoption of digital health-enabled injectors, expansion of biologics pipelines, growing focus on adherence-enhancing drug delivery, increasing use of connected medical devices. Major trends in the forecast period include increasing adoption of auto-injector devices, rising demand for wearable injection systems, growing use of biologic self-administered therapies, expansion of patient-centric drug delivery designs, enhanced focus on safety and dose accuracy.
The increasing prevalence of diabetes is expected to drive the expansion of the self-injections market in the coming years. Diabetes is a medical condition in which the pancreas, the organ responsible for insulin production, generates insufficient insulin, resulting in impaired blood sugar regulation and leading to serious complications such as cardiovascular disease, vision impairment, and kidney disorders. Self-injection devices allow individuals with diabetes to administer insulin and other therapies independently, helping them maintain optimal blood glucose levels and prevent excess sugar accumulation without reliance on healthcare professionals. For example, in November 2025, according to Diabetes Care, a United States-based international peer-reviewed medical journal, an estimated 634.8 million adults, representing 12 percent of the global adult population, were living with impaired glucose tolerance in 2024, a figure projected to rise to 846.5 million adults or 12.9 percent of the global adult population by 2050. As a result, the rising number of people with diabetes is contributing significantly to the growth of the self-injections market.
Leading companies operating in the self-injections market are increasingly prioritizing innovations in drug-delivery technologies, including hands-free and hidden-needle subcutaneous systems designed to simplify patient self-administration of large-volume biologic therapies. Hands-free, hidden-needle subcutaneous delivery involves wearable injectors that automatically deliver medication while concealing the needle, thereby improving comfort, safety, and ease of use. For instance, in November 2023, Enable Injections Inc., a United States-based drug-delivery technology company, received its first approval from the United States Food and Drug Administration for the enFuse large-volume wearable injector for use with EMPAVELI (pegcetacoplan). This compact, mechanical, body-worn system is capable of delivering up to 25 milliliters subcutaneously and supports both self-administration and in-clinic use, offering features such as hands-free operation and minimal disruption to patients’ daily activities. The enFuse platform enhances convenience, promotes home-based care, and improves the overall patient experience for large-volume therapy delivery.
In May 2024, Enable Injections, Inc., a United States-based developer and manufacturer of the enFuse wearable drug-delivery platform, entered into a partnership with Roche Holding AG to apply the enFuse system to selected Roche molecules for subcutaneous administration. Through this collaboration, Enable Injections seeks to broaden access to large-volume self-administration therapies by enabling a transition from intravenous treatments to at-home subcutaneous delivery for a wider patient population. Roche Holding AG is a Switzerland-based pharmaceutical company with a strong focus on biologics and drug-device combination development.
Major companies operating in the self-injections market are AbbVie Inc., Antares Pharma Inc., Baxter International Inc., Bayer AG, Becton Dickinson and Company, Bristol-Myers Squibb Company, Credence MedSystems Inc., Dali Medical Devices Ltd., Eli Lilly and Company, Enable Injections Inc., Gerresheimer AG, Insulet Corporation, Merck & Co. Inc., Owen Mumford Limited, Pfizer Inc., PharmaJet Inc., Recipharm AB, Schott AG, SHL Group Limited, Terumo Corporation, West Pharmaceutical Services Inc., Wilhelm Haselmeier GmbH & Co. KG, Ypsomed Holding AG, APTAR PHARMA INDIA PVT LTD, Bespak Europe Ltd., Bioject Medical Technologies Inc., Catalent Inc., Crossject SA, Injex Pharma AG, Medeca Pharma AB, Medimop Medical Projects Ltd., Mylan N.V., Nemera Development S.A., Noble Medical Inc.
North America was the largest region in the self-injections market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the self-injections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the self-injections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the self-injections market by increasing costs of imported medical-grade plastics, precision springs, electronic components, and sterile manufacturing equipment used in auto-injectors and wearable devices. Pharmaceutical and device manufacturers in North America and Europe are most affected due to cross-border component sourcing, while Asia-Pacific faces cost pressure on device exports. These tariffs are raising device production costs and pricing pressures. However, they are also encouraging localized device assembly, regional supplier partnerships, and investment in domestic medical device manufacturing capabilities.
The self-injections market research report is one of a series of new reports that provides self-injections market statistics, including self-injections industry global market size, regional shares, competitors with a self-injections market share, detailed self-injections market segments, market trends and opportunities, and any further data you may need to thrive in the self-injections industry. This self-injections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Self-injection refers to the act of administering medications or drugs through a device by an individual to themselves without the assistance of a medical professional. This practice allows patients to independently manage their medication regimen.
The primary types of self-injections encompass devices and formulations. These devices enable patients to self-administer medications that require injection without relying on medical professionals. Self-injection devices are utilized for various routes of administration such as skin, circulatory or musculoskeletal systems, organs, and the central nervous system. Dosage types include single-dose and multi-dose, catering to applications in autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, among others. These devices are distributed through various channels including hospitals, pharmacies, clinics, chemists, and online pharmacies.
The self injections market consists of sales of auto-injectors, needle-free injectors, pen injectors and wearable injectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The self-injections market size is expected to see strong growth in the next few years. It will grow to $15.05 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for self-care therapies, rising adoption of digital health-enabled injectors, expansion of biologics pipelines, growing focus on adherence-enhancing drug delivery, increasing use of connected medical devices. Major trends in the forecast period include increasing adoption of auto-injector devices, rising demand for wearable injection systems, growing use of biologic self-administered therapies, expansion of patient-centric drug delivery designs, enhanced focus on safety and dose accuracy.
The increasing prevalence of diabetes is expected to drive the expansion of the self-injections market in the coming years. Diabetes is a medical condition in which the pancreas, the organ responsible for insulin production, generates insufficient insulin, resulting in impaired blood sugar regulation and leading to serious complications such as cardiovascular disease, vision impairment, and kidney disorders. Self-injection devices allow individuals with diabetes to administer insulin and other therapies independently, helping them maintain optimal blood glucose levels and prevent excess sugar accumulation without reliance on healthcare professionals. For example, in November 2025, according to Diabetes Care, a United States-based international peer-reviewed medical journal, an estimated 634.8 million adults, representing 12 percent of the global adult population, were living with impaired glucose tolerance in 2024, a figure projected to rise to 846.5 million adults or 12.9 percent of the global adult population by 2050. As a result, the rising number of people with diabetes is contributing significantly to the growth of the self-injections market.
Leading companies operating in the self-injections market are increasingly prioritizing innovations in drug-delivery technologies, including hands-free and hidden-needle subcutaneous systems designed to simplify patient self-administration of large-volume biologic therapies. Hands-free, hidden-needle subcutaneous delivery involves wearable injectors that automatically deliver medication while concealing the needle, thereby improving comfort, safety, and ease of use. For instance, in November 2023, Enable Injections Inc., a United States-based drug-delivery technology company, received its first approval from the United States Food and Drug Administration for the enFuse large-volume wearable injector for use with EMPAVELI (pegcetacoplan). This compact, mechanical, body-worn system is capable of delivering up to 25 milliliters subcutaneously and supports both self-administration and in-clinic use, offering features such as hands-free operation and minimal disruption to patients’ daily activities. The enFuse platform enhances convenience, promotes home-based care, and improves the overall patient experience for large-volume therapy delivery.
In May 2024, Enable Injections, Inc., a United States-based developer and manufacturer of the enFuse wearable drug-delivery platform, entered into a partnership with Roche Holding AG to apply the enFuse system to selected Roche molecules for subcutaneous administration. Through this collaboration, Enable Injections seeks to broaden access to large-volume self-administration therapies by enabling a transition from intravenous treatments to at-home subcutaneous delivery for a wider patient population. Roche Holding AG is a Switzerland-based pharmaceutical company with a strong focus on biologics and drug-device combination development.
Major companies operating in the self-injections market are AbbVie Inc., Antares Pharma Inc., Baxter International Inc., Bayer AG, Becton Dickinson and Company, Bristol-Myers Squibb Company, Credence MedSystems Inc., Dali Medical Devices Ltd., Eli Lilly and Company, Enable Injections Inc., Gerresheimer AG, Insulet Corporation, Merck & Co. Inc., Owen Mumford Limited, Pfizer Inc., PharmaJet Inc., Recipharm AB, Schott AG, SHL Group Limited, Terumo Corporation, West Pharmaceutical Services Inc., Wilhelm Haselmeier GmbH & Co. KG, Ypsomed Holding AG, APTAR PHARMA INDIA PVT LTD, Bespak Europe Ltd., Bioject Medical Technologies Inc., Catalent Inc., Crossject SA, Injex Pharma AG, Medeca Pharma AB, Medimop Medical Projects Ltd., Mylan N.V., Nemera Development S.A., Noble Medical Inc.
North America was the largest region in the self-injections market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the self-injections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the self-injections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the self-injections market by increasing costs of imported medical-grade plastics, precision springs, electronic components, and sterile manufacturing equipment used in auto-injectors and wearable devices. Pharmaceutical and device manufacturers in North America and Europe are most affected due to cross-border component sourcing, while Asia-Pacific faces cost pressure on device exports. These tariffs are raising device production costs and pricing pressures. However, they are also encouraging localized device assembly, regional supplier partnerships, and investment in domestic medical device manufacturing capabilities.
The self-injections market research report is one of a series of new reports that provides self-injections market statistics, including self-injections industry global market size, regional shares, competitors with a self-injections market share, detailed self-injections market segments, market trends and opportunities, and any further data you may need to thrive in the self-injections industry. This self-injections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Self-injection refers to the act of administering medications or drugs through a device by an individual to themselves without the assistance of a medical professional. This practice allows patients to independently manage their medication regimen.
The primary types of self-injections encompass devices and formulations. These devices enable patients to self-administer medications that require injection without relying on medical professionals. Self-injection devices are utilized for various routes of administration such as skin, circulatory or musculoskeletal systems, organs, and the central nervous system. Dosage types include single-dose and multi-dose, catering to applications in autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, among others. These devices are distributed through various channels including hospitals, pharmacies, clinics, chemists, and online pharmacies.
The self injections market consists of sales of auto-injectors, needle-free injectors, pen injectors and wearable injectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Self-Injections Market Characteristics
3. Self-Injections Market Supply Chain Analysis
4. Global Self-Injections Market Trends and Strategies
5. Self-Injections Market Analysis of End Use Industries
7. Global Self-Injections Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Self-Injections Total Addressable Market (TAM) Analysis for the Market
9. Self-Injections Market Segmentation
10. Self-Injections Market Regional and Country Analysis
11. Asia-Pacific Self-Injections Market
12. China Self-Injections Market
13. India Self-Injections Market
14. Japan Self-Injections Market
15. Australia Self-Injections Market
16. Indonesia Self-Injections Market
17. South Korea Self-Injections Market
18. Taiwan Self-Injections Market
19. South East Asia Self-Injections Market
20. Western Europe Self-Injections Market
21. UK Self-Injections Market
22. Germany Self-Injections Market
23. France Self-Injections Market
24. Italy Self-Injections Market
25. Spain Self-Injections Market
26. Eastern Europe Self-Injections Market
27. Russia Self-Injections Market
28. North America Self-Injections Market
29. USA Self-Injections Market
30. Canada Self-Injections Market
31. South America Self-Injections Market
32. Brazil Self-Injections Market
33. Middle East Self-Injections Market
34. Africa Self-Injections Market
36. Self-Injections Market Competitive Landscape and Company Profiles
37. Self-Injections Market Other Major and Innovative Companies
40. Self-Injections Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Self-Injections Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses self-injections market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for self-injections? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The self-injections market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Devices; Formulations2) By Dosage: Single Dose; Multi Dose
3) By Application: Autoimmune Diseases; Hormonal Disorders; Orphan Diseases; Pain Management; Other Applications
4) By Distribution Channel: Chemist; Online Pharmacies
Subsegments:
1) By Devices: Pre-Filled Syringes; Auto-Injectors; Microneedle Devices; Wearable Injectors2) By Formulations: Biologics; Small Molecules; Combination Products
Companies Mentioned: AbbVie Inc.; Antares Pharma Inc.; Baxter International Inc.; Bayer AG; Becton Dickinson and Company; Bristol-Myers Squibb Company; Credence MedSystems Inc.; Dali Medical Devices Ltd.; Eli Lilly and Company; Enable Injections Inc.; Gerresheimer AG; Insulet Corporation; Merck & Co. Inc.; Owen Mumford Limited; Pfizer Inc.; PharmaJet Inc.; Recipharm AB; Schott AG; SHL Group Limited; Terumo Corporation; West Pharmaceutical Services Inc.; Wilhelm Haselmeier GmbH & Co. KG; Ypsomed Holding AG; APTAR PHARMA INDIA PVT LTD; Bespak Europe Ltd.; Bioject Medical Technologies Inc.; Catalent Inc.; Crossject SA; Injex Pharma AG; Medeca Pharma AB; Medimop Medical Projects Ltd.; Mylan N.V.; Nemera Development S.A.; Noble Medical Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Self-Injections market report include:- AbbVie Inc.
- Antares Pharma Inc.
- Baxter International Inc.
- Bayer AG
- Becton Dickinson and Company
- Bristol-Myers Squibb Company
- Credence MedSystems Inc.
- Dali Medical Devices Ltd.
- Eli Lilly and Company
- Enable Injections Inc.
- Gerresheimer AG
- Insulet Corporation
- Merck & Co. Inc.
- Owen Mumford Limited
- Pfizer Inc.
- PharmaJet Inc.
- Recipharm AB
- Schott AG
- SHL Group Limited
- Terumo Corporation
- West Pharmaceutical Services Inc.
- Wilhelm Haselmeier GmbH & Co. KG
- Ypsomed Holding AG
- APTAR PHARMA INDIA PVT LTD
- Bespak Europe Ltd.
- Bioject Medical Technologies Inc.
- Catalent Inc.
- Crossject SA
- Injex Pharma AG
- Medeca Pharma AB
- Medimop Medical Projects Ltd.
- Mylan N.V.
- Nemera Development S.A.
- Noble Medical Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 11.04 Billion |
| Forecasted Market Value ( USD | $ 15.05 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 35 |
